



Cancer Research

AN OFFICIAL JOURNAL OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH



February 1, 1997
Volume 57 • Number 3
PP. 351-558
ISSN 0008-5472 • CNREA 8



AMERICAN ASSOCIATION FOR CANCER RESEARCH SCIENTIFIC CONFERENCES

MARCH 7-12, 1997

***Basic and Clinical Aspects of
Breast Cancer***

Chairpersons: J. Carl Barrett, Research Triangle
Park, NC; Karen S.H. Antman, New York, NY;
Mary-Claire King, Seattle, WA
Keystone Resort, Keystone, CO

APRIL 12-16, 1997

88th Annual Meeting

Chairperson: Frederick P. Li, Boston, MA
Co-Chairpersons: Clara Derber Bloomfield,
Buffalo, NY; Stephen H. Friend, Seattle, WA
San Diego Convention Center, San Diego, CA

JUNE 7-11, 1997

Cancer of the Central Nervous System

Conference with Neurosurgery Joint Section on
Tumors

Chairpersons: Peter McL. Black, Boston, MA;
Webster K. Cavenee, La Jolla, CA
Loew's Coronado Bay Resort, San Diego, CA

SEPTEMBER 9-13, 1997

Molecular Genetics of Cancer

Conference with the European Association for
Cancer Research

Chairpersons: Eric J. Stanbridge, Irvine, CA;
Walter Bodmer, Oxford, England
Hertford College, Oxford, England

SEPTEMBER 26-30, 1997

Tumor Suppressor Genes

Chairpersons: Stephen H. Friend, Seattle, WA;
Philip Branton, Montreal, Quebec, Canada
Victoria Conference Centre, Victoria, BC, Canada

OCTOBER 17-21, 1997

***Gene Regulation in Differentiation
and Development***

Chairpersons: Robert Eisenman, Seattle, WA;
Elaine V. Fuchs, Chicago, IL
The Sagamore Resort, Bolton Landing (Lake
George), NY

DECEMBER 1997

Epigenetics of Cancer

Chairperson: Peter A. Jones, Los Angeles, CA
Location in Puerto Rico to be Announced

JANUARY 9-13, 1998

***Colorectal Cancer — Biology, Treatment,
and Prevention***

Joint Meeting with the American Society of Clinical
Oncology

Chairpersons: Robert J. Mayer, Boston, MA; One
Additional Chairperson to be Announced
Renaissance Esmeralda Resort, Indian Wells
(Palm Springs), CA

JANUARY 1998

Angiogenesis and Cancer

Chairpersons: Judah Folkman, Boston, MA;
Michael Klagsbrun, Boston, MA
Location in Orlando, FL to be Announced

FEBRUARY 16-21, 1998

***Innovative Molecular Biology Approaches
to the Prevention, Diagnosis, and Therapy
of Cancer***

Joint Meeting with the Japanese Cancer
Association

Chairpersons: Edward Bresnick, Worcester, MA;
Kaoru Abe, Tokyo, Japan
Maui Marriott Resort, Maui, HI

AACR members will receive brochures on the
above conferences as soon as they are available.
Nonmembers should call or write:

American Association for Cancer Research
Public Ledger Building, Suite 816
150 South Independence Mall West
Philadelphia, PA 19106-3483
215-440-9300 • 215-440-9313 (FAX)
E-Mail: aacr@aacr.org

*For regular updates to this list visit the AACR's
Website, <http://www.aacr.org>*

**PROFESSOR AND CHAIR
DEPARTMENT OF PHARMACOLOGY
AND TOXICOLOGY
DARTMOUTH MEDICAL SCHOOL**

Applications are invited from researchers in the area of cancer biology for the position of Professor and Chair of the Department of Pharmacology and Toxicology at Dartmouth Medical School. The Department participates in the education of M.D., Ph.D., and M.D./Ph.D. students. Members of the faculty conduct research on a wide range of interdisciplinary topics including cancer biology, with a strong emphasis on cellular and molecular pharmacology (information available at <http://www.dartmouth.edu/dms/pharmtox/>). The faculty maintain research and academic ties to other departments at Dartmouth Medical School, the Norris Cotton Cancer Center, Dartmouth College, and the Veterans Administration Medical Center.

Applicants should have an active research program and a strong record of scientific and scholarly achievement commensurate with that expected of the holder of an endowed chair which will accompany this position. They should have a strong commitment to excellence in education, and have the leadership qualities necessary for developing the faculty and promoting the research and academic programs of the Department.

Letters of application, accompanied by a curriculum vitae, names and addresses of three references, and a summary of current research activities and support, should be sent to Pharmacology-Toxicology Search Committee, Office of the Dean, Dartmouth Medical School, Hanover, NH 03756.

Dartmouth College is an Affirmative Action/Equal Opportunity employer and encourages applications from women and members of minority groups.

CLINICAL TRIALS PROGRAM

**PROSTATE CANCER INITIATIVE
OF THE
CANCER RESEARCH INSTITUTE**

The Cancer Research Institute announces the availability of Clinical Research Seed Grants to support Phase I or Phase I/II trials. The Institute is planning to make individual grants in the amount of \$150,000 over two years to support clinical research aimed at testing novel immunotherapies for advanced prostate cancer. The Cancer Research Institute does not provide funds for indirect costs. The deadline for receiving applications (including the clinical protocol) is April 15, 1997. The clinical research may be conducted in the United States or abroad, at nonprofit medical centers or hospitals.

For applications, please contact:

Ms. Lynne Harmer
Director of Grants Administration
Cancer Research Institute

681 Fifth Avenue
New York, NY 10022-4209
212-688-7515, FAX: 212-832-9376
or e-mail: cancerres@aol.com



**AMERICAN CANCER SOCIETY
REQUEST FOR APPLICATIONS
HEALTH POLICY AND
OUTCOMES RESEARCH—
PROSTATE CANCER**

The American Cancer Society is earmarking \$3,000,000 in 1997 for Health Policy and Outcomes Research in Prostate Cancer. Application is open to independent investigators at any stage of their careers.

The first deadline is April 1, 1997. Subsequent deadlines will be October 15, 1997, and on those same dates through 1999. The grants will be for three years, up to \$250,000 per year, including 25% indirect costs, and will be renewable as long as this remains a targeted priority area. Please contact the Office of Sponsored Programs at your institution after January 1, 1997, for a special RFA application form, or download from <http://www.cancer.org>.

Questions concerning this RFA should be directed to Dr. Ralph Vogler at (404) 329-7542 or Dr. Frank Baker at (404) 329-7795.



**FACULTY LEVEL POSITIONS
IN GENETICS**

The Southwest Foundation for Biomedical Research invites applications for two faculty-level positions in the Department of Genetics. One of the positions will require an interest in the genetics of cancer; the other position will require an interest in the molecular genetics of other research areas complementary to our existing programs. Ongoing research in the Department of Genetics includes genetic studies of common diseases (atherosclerosis, diabetes, obesity, hypertension, osteoporosis), gene mapping (nonhuman primates and marsupials), gene regulation during development, X-chromosome inactivation, and genetics of infectious diseases. Our existing program in cancer focuses on UV-induction of melanoma in experimental animal models. The successful candidates will be expected to develop strong independent research programs, and will have opportunities to collaborate in ongoing research. Unique resources available to our department include large human pedigrees, and large pedigreed colonies of nonhuman primates and marsupials. Ample opportunities exist for affiliations with local academic institutions. Applications are invited from scientists at any academic level. A doctoral level degree in a biological science is required. The positions present an excellent opportunity for creative scientists in an established genetics department. Please mail curriculum vitae, statement of research interests, and names, addresses, and telephone numbers of three references to: Director of Human Resources (632-CR), SFBR, P.O. Box 760549, San Antonio, Texas 78245-0549.

Equal Opportunity Employer.

**AMERICAN CANCER SOCIETY
REQUEST FOR APPLICATIONS
NOVEL IDEAS IN PROSTATE
CANCER CELL BIOLOGY**

The American Cancer Society has earmarked \$1.5 million in 1997 for Novel Ideas in Prostate Cancer Cell Biology. Application is open to independent investigators at any stage of their careers.

The first deadline for these applications is April 1, 1997. Subsequent deadlines will be October 15, 1997, and on those same dates through 1999. The grants awarded in response to this RFA will be for three years, up to \$65,000 per year, including 25% indirect costs, and will be renewable as long as this remains a targeted priority area. Please contact the Office of Sponsored Programs at your institution after January 1, 1997, for a special RFA application form, or download from <http://www.cancer.org>.

Questions concerning this RFA should be directed to Dr. Peter Ove (404) 329-7552.

**AMERICAN CANCER SOCIETY
REQUEST FOR APPLICATIONS
BEHAVIOR, PSYCHOSOCIAL,
QUALITY OF LIFE—
PROSTATE CANCER**

The American Cancer Society is earmarking \$3,000,000 in 1997 for Behavioral, Psychosocial, and Quality of Life Research relating to Prostate Cancer. Application is open to independent investigators at any stage of their careers.

The first deadline for these applications is April 1, 1997. Subsequent deadlines will be October 15, 1997, and on those same dates through 1999. The grants will be for three years, up to \$250,000 per year, including 25% indirect costs, and will be renewable as long as this remains a targeted priority area. Please contact the Office of Sponsored Programs at your institution after January 1, 1997, for a special RFA application form, or download it from <http://www.cancer.org>.

Questions concerning this Request for Applications should be directed to Dr. Ralph Vogler (404) 329-7542 or Dr. Frank Baker (404) 329-7795.

CANCER RESEARCH CAMPAIGN

Beatson International Cancer Conference

Co-sponsored by

ASSOCIATION FOR INTERNATIONAL CANCER RESEARCH

CANCER: FROM PEDIGREE TO PROTEIN
SUNDAY 6TH - WEDNESDAY 9TH JULY 1997
GLASGOW, SCOTLAND

KEYNOTE SPEAKER

W Cavenee (USA)

SUSCEPTIBILITY

A. Bale (USA), A. Balmain (UK), S. Jackson (UK), J. Peto (UK), B. Ponder (UK)

CELL CYCLE

J. Bartek (DK), R. DePinho (USA), N. LaThangue (UK), J. Massagué (USA), C. Sherr (USA)

SUPPRESSOR GENE FUNCTION

W. Wright (USA), J. Holt (USA), K. Parkinson (UK), O. Pereira-Smith (USA), E. White (USA)

CELL BEHAVIOUR

R. Assoian (USA), K. Burridge (USA), K. Dane (DK), J. Collard (NL), E. Ruoslahti (USA)

TRANSLATIONAL RESEARCH

D. Lane (UK), C. Marshall (UK), F. McCormick (USA), B. Villeponteau (USA)

LATE BREAKING NEWS

Speakers to be invited shortly before the conference

for further information please contact:

TRICIA WHEELER

Conference Co-ordinator,

Beatson Institute for Cancer Research, Gartscube Estate,
Switchback Road, Bearsden, Glasgow G61 1BD.

Tel: +44 141 942 0855 • Fax: +44 141 942 6521

e-mail: gvpa20@udcf.gla.ac.uk

Web site: <http://www.beatson.gla.ac.uk/beatson/conf>

Deadline for registration APRIL 4th 1997

Faculty Position Open

Biostatistics Core Director
Washington University Medical School

New joint faculty position with the Dept. of Biostatistics and the Washington University Cancer Center.

Primary Responsibility: To create and build a biostatistics core that provides design and analytical services to Cancer Center members for new and ongoing basic, clinical, and prevention and control research.

Qualifications: Candidates should have a Ph.D. in Biostatistics and minimum of 3 years experience in working with clinical trials.

Send curriculum vitae to:

Attn: Anita Harrison

Washington University Cancer Center

Box 8056, 4960 Children's Place

St. Louis, MO 63110



**LATE-BREAKING RESEARCH SESSION
AT THE AACR ANNUAL MEETING
Tuesday, April 15, 1997**

Time has been set aside for the presentation of 4-5 definitive reports of highly significant and timely findings in the field. Criteria for the selection of these presentations and instructions for submission of abstracts are as follows:

INSTRUCTIONS FOR SUBMISSION OF LATE-BREAKING ABSTRACTS

1. The work to be presented must be of major novelty and significance, *e.g.*, the characterization of a new gene in familial cancer or the discovery of a new diagnostic marker, and should not have been previously published in a peer-reviewed scientific journal or presented at a national meeting.
2. The abstract must be sponsored by an AACR member in good standing (dues paid for 1997).
3. Each member in good standing may sponsor only **one** abstract for this session whether or not he or she sponsored an abstract last November for the regular annual meeting program. If an associate member is the **sponsor**, the abstract must also be **endorsed** by an active or corresponding member in good standing. In this case, the **endorser** does **not** forfeit the opportunity to **sponsor** a late-breaking abstract.
4. Abstracts must be typed on **one** side of **one** sheet of white paper.
5. All text on the page must fit within an area 6 1/2" wide and 9" high (16.5 cm X 22.9 cm) with margins of at least 1" (2.5 cm) on the top, bottom, and sides of the page.
6. Each abstract must be accompanied by a covering letter from the sponsor explaining why the work is novel and significant enough to be considered for this late-breaking research session and certifying that the findings became available **after** the annual meeting abstract deadline of November 12, 1996. This letter must contain the sponsor's complete mailing address, FAX number, and E-mail address (if available) so that we can communicate the scheduling decision of the Program Committee.
7. Abstracts and covering letters must be received in the AACR Office by 5:00 p.m. Eastern Time on **March 7, 1997**. FAX transmissions are **not** acceptable. Carrying envelopes should be clearly marked "Late-Breaking Abstract," and should be addressed to American Association for Cancer Research, Public Ledger Building, Suite 816, 150 South Independence Mall West, Philadelphia, PA 19106-3483. If you wish to receive acknowledgment of receipt of your abstract, enclose a self-addressed post card with appropriate postage affixed. Accepted abstracts will not be published since they will be received after the *Proceedings of the American Association for Cancer Research* has been printed; however, they will be distributed at the session in San Diego.
8. A special subcommittee of the Program Committee appointed by President Louise C. Strong will select the papers to be presented. Presenters of accepted papers will be notified via FAX no later than **March 24, 1997**.

AACR SPECIAL CONFERENCE IN CANCER RESEARCH
Co-Sponsored by the Joint Section on Tumors of the American Association of
Neurological Surgeons and Congress of Neurological Surgeons

Cancer of the Central Nervous System



June 7-11, 1997
Loews Coronado Bay Resort
San Diego, CA

CONFERENCE CO-CHAIRPERSONS

Webster K. Cavenee / La Jolla, CA **Peter McL. Black** / Boston, MA

PROGRAM COMMITTEE

William F. Chandler / Ann Arbor, MI **Mark D. Noble** / Salt Lake City, UT
Joseph Piepmeier / New Haven, CT **Bernd R. Seizinger** / Boston, MA
Jean Y. J. Wang / La Jolla, CA

CONFERENCE PROGRAM

Keynote Address

Charles B. Wilson / San Francisco, CA

Triumphs and Challenges of Present Diagnosis and Management

Catherine Dumas-Duport / Paris, France
Peter McL. Black / Boston, MA
Jay S. Loeffler / Boston, MA
Victor A. Levin / Houston, TX

Neurobiology and Developmental Biology

Fred H. Gage / La Jolla, CA
Mark D. Noble / Salt Lake City, UT

Genetic Predispositions to CNS Tumors

Jean Y. J. Wang / La Jolla, CA
Lawrence A. Donehower / Houston, TX
Eric C. Holland / Bethesda, MD
Nikolai Kley / Boston, MA

Molecular Genetics

David N. Louis / Boston, MA
Huei-Jen Su Huang / La Jolla, CA
Otmar D. Wiestler / Bonn, Germany

New Targets for Therapy

Mark L. Rosenblum / Detroit, MI
David Hockenberry / Seattle, WA
Jerry W. Shay / Dallas, TX
Kevin Webster / Princeton, NJ

Receptor Mediated Growth Control

Charles D. Stiles / Boston, MA
Webster K. Cavenee / La Jolla, CA
Lewis T. Williams / San Francisco, CA

Novel Therapies


Xandra O. Breakefield / Boston, MA
Jackson B. Gibbs / West Point, PA
Judah Folkman / Boston, MA
Frank McCormick / San Francisco, CA

ADDITIONAL SPEAKERS TO BE ANNOUNCED

Application Deadline: March 14, 1997

Information and Application Forms:

American Association for Cancer Research
Public Ledger Building, Suite 816
150 South Independence Mall West
Philadelphia, PA 19106-3483
215-440-9300 • 215-440-9313 (FAX)
E-mail: aacr@aacr.org
Website: <http://www.aacr.org>



Featured on the cover of this issue is Peter A. Jones,¹ Professor of Biochemistry, Molecular Biology, and Urology at the University of Southern California School of Medicine and Director of the USC/Norris Comprehensive Cancer Center. Born in Cape Town, South Africa, Dr. Jones earned his B.S. from the University College of Rhodesia (London) in 1969, and his Ph.D. from the University of London in 1973. With the aid of numerous fellowships and awards, his postdoctoral studies resulted in receipt of the D.Sc. from the University of Zimbabwe in 1983. He was a National Institutes of Health postdoctoral fellow at the Childrens Hospital of Los Angeles from 1973 to 1975, and after several teaching and research appointments in South Africa, he returned to the U.S. in 1977 to join the USC, where he advanced from Assistant Professor of Pediatrics and Biochemistry (1977–1981) to full professorship in 1985. He was named Director of the USC/Norris Comprehensive Cancer Center in 1993, after serving as Associate Director for Basic Research for 9 years.

Dr. Jones' major research efforts are in the area of gene mutations in cancer development, and he is an outstanding leader in the study of DNA methylation, exploring its role in controlling gene expression and in inducing a large proportion of cancer-causing mutations in humans. He introduced the use of 5-azacytidine as an agent to modify DNA methylation patterns and to induce the expression of silent genes (*Cell*, 20: 85, 1980). He was among the first to show that several hot spots for mutation in the *p53* gene were sites for DNA methylation [*Science* (Washington, DC), 249: 1288, 1990], and he has studied the mechanism of mutation at 5-methylcytosine in greater detail. These experiments led to the demonstration that DNA methyltransferase itself is capable of acting as a cytosine deaminase, thus suggesting possible new routes to mutagenesis (*Cell*, 71: 1073, 1992).

Dr. Jones has led the development of translational research at the USC/Norris Comprehensive Cancer Center by initiating a program in bladder cancer in close cooperation with the Departments of Urology and Pathology. This research has identified the existence of putative tumor suppressor genes on chromosome 9, defined the role of the *p53* gene in bladder cancer, and developed strong interactions with the Cancer Epidemiology Program, emphasizing the importance of mu-

tational spectra in the *p53* gene in understanding the genesis of human cancer (*Cancer Res.*, 54: 784, 1994).

Dr. Jones' research has been supported by peer-reviewed grants since 1978 and by an Outstanding Investigator Grant from the National Cancer Institute (NCI) since 1989. He has published 118 peer-reviewed papers and serves on the editorial boards of several prestigious journals, including *Cancer Research*, for which he has been an Associate Editor since 1983. He has also lectured widely throughout the world. He has served on many national committees and is a member of several professional societies, including the American Association for Cancer Research (AACR), of which he has been an active member since 1978. Dr. Jones has dedicated much time and energy to serving on AACR committees and fostering the society's growth as a dynamic biomedical research organization. He served on the Board of Directors from 1989–1992, and he is currently a member of the Publications Committee (1994–) and was recently appointed Chairperson of the Finance Committee (1996–). He has also been Chairperson of the Special Memberships Committee (1993), the Local Arrangements Committee (1986), and the Biology Section of the Program Committee (1989).

Under Dr. Jones' directorship, the USC/Norris Comprehensive Cancer Center utilizes its location in the large urban, multicultural environment of Los Angeles to study questions of racial and ethnic differences in cancer incidence and morbidity in its research programs. The development of the Center began in 1966 with the award of an NCI planning grant to the USC School of Medicine. The Center was inaugurated as the Los Angeles County-USC Cancer Center in mid-1971 and was awarded its first Core Grant and recognition as an NCI-designated comprehensive cancer center in 1973. The Center has two interdependent components: (a) the scientific research and educational activities that are conducted by University faculty and supported by the Center's administration; and (b) the clinical care and patient and professional education that are provided in the Kenneth Norris Jr. Cancer Hospital, the LAC + USC Medical Center, and the Childrens Hospital of Los Angeles. The leadership structure of the Center has been deliberately designed to promote the concept of "centeredness" and to facilitate the development of interdisciplinary cancer research and treatment at USC. Under the direction of Dr. Jones, the research structure of the Center has been organized into five discipline-based and four disease-based programs: Gene Regulation; Cell Biology; Developmental Therapeutics and Clinical Trials; Cancer Epidemiology; Cancer Control Research; Genitourinary Cancer; Gastrointestinal Cancer; Breast Cancer; and Hematologic Malignancies/Retroviral Disease. The disease-based programs have become very successful in providing foci for translational research.

The Center's headquarters building (pictured to the left in bottom cover photo) on the Health Sciences Campus of the University was completed in 1983 with the aid of an \$11.8 million NCI construction grant and includes basic research laboratories as well as inpatient and outpatient hospital facilities. The Center has recently opened a major addition to its headquarters building—the Dr. Norman Topping Tower (pictured to the right in the bottom cover photo). Eight years in the planning and construction, the Topping Tower is the embodiment of the Center's mission: to reduce the burden of cancer morbidity and mortality in Southern California through the translation of research findings to patient care and education. The Topping Tower was also built with the assistance of a \$1.2 million NCI construction grant. The new building houses greatly expanded outpatient facilities, two floors of research laboratories, offices for clinical faculty, and research and office space for faculty doing epidemiological and cancer control research.

¹ Photograph by Mario Lopez.